Gilead says its twice-yearly shot cut HIV infections by 96% in trial
Publishing timestamp: 2024-09-12 13:29:54
Summary
Gilead's twice-yearly shot reduced HIV infections by 96% in second large study, setting the stage for likely FDA approval of lenacapavir for HIV prevention. The drug was found to be 89% more effective than Truvada, with no new safety concerns reported. Shares of Gilead climbed more than 1% on Thursday.
Sentiment: POSITIVE
Tickers: GILD,
Keywords: science, business news, hiv and aids, social issues, health care industry, gilead sciences inc, pharmaceuticals,
Source: https://www.cnbc.com/2024/09/12/gilead-lenacapavir-cut-hiv-infections-by-96percent-in-trial.html